Marshall Wace is a hedge fund manager that primarily focuses on quantitative, systematic, and fundamental investment strategies, specializing in long/short equity. The firm also engages in venture capital, particularly in privately owned healthcare companies nearing public flotation, and utilizes its proprietary "Trade Optimized Portfolio System" (TOPS) to analyze vast data and crowdsourced investment ideas.
Portfolio
10
Fund Size
—
Top Stage
Series E
Last 12 Mo
1
Stage Distribution
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Attovia Therapeutics | Series C | $90M | Apr 2025 |
| Pathalys Pharma, Inc. | Series B | $105M | Aug 2024 |
| OnCusp Therapeutics | Series A | $100M | Jan 2024 |
| BlueWhale Bio, Inc. | Seed | $18M | Sep 2023 |
| Tipalti | Series F | $270M | Dec 2021 |
| TRM Labs | Series B | $60M | Dec 2021 |
| Varo | Series E | $510M | Sep 2021 |
| Varo Bank | Series E | $510M | Sep 2021 |
| InBrace | Series D | $102M | Sep 2021 |
| Pine Labs | Growth | $285M | May 2021 |
Top Co-Investors
Lone Pine Capital3 shared
Eldridge2 shared
Warburg Pincus2 shared
The Rise Fund2 shared
BlackRock2 shared
Novo Holdings2 shared
Deep Track Capital1 shared
Sanofi Ventures1 shared
Goldman Sachs Alternatives1 shared
Cormorant Asset Management1 shared
Endeavour Vision1 shared
Vivo Capital1 shared
venBio1 shared
OrbiMed1 shared
F-Prime Capital1 shared
Sofinnova Partners1 shared
Catalio Capital Management1 shared
Moore Strategic Ventures1 shared
Temasek Holdings1 shared
Tiger Global Management1 shared
Last updated: 3 March 2026